Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …

Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral …

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

Importance The monoclonal antibody combination of casirivimab and imdevimab reduced
viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous …

Objective To assess the real-world effectiveness of casirivimab and imdevimab (CAS+ IMD)
versus no COVID-19 antibody treatment among patients diagnosed with COVID-19 in the …

Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-
COV®) reduced viral load, hospitalisation, or death when administered 1: 1 as an …

Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …

Abstract Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged
combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal …

Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …